Full-Time

Publishing Manager

Regulatory Affairs

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree or equivalent.
  • At least 5 years of experience as a regulatory Publisher in a pharmaceutical company or CRO, with 2+ years in a management role.
  • Experience leading the submission of MAA, INDs, NDAs, BLAs, Master Files, etc., formatted according to international eCTD requirements.
  • Clinical report and global submission dossier publishing/compilation experience in the pharmaceutical or related industry.
  • Experience with electronic clinical document publishing standards/formats and global regulatory submission publishing standards/formats (e.g., eCTD, EU CTR).
  • Working knowledge of publishing tools (e.g., DXC, eCTD Xpress, Veeva), global submission validation tools, Document Management systems, Toolbox, HA electronic submission gateways, IRIS, CTIS, MS Office tools.
  • Familiarity with global Clinical and Regulatory HA requirements (e.g., FDA, ICH, EMA, MENA region, CH, MHRA).
  • Strong interpersonal and project management skills, with experience working in a complex, global cross-functional organization.
  • Highly motivated, organized, and detail-oriented team player.
  • Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines.
  • Ability to readily adjust to change in a fast-paced environment and multitask.
  • Positive attitude and ability to effectively collaborate with peers, stakeholders, and cross-functional colleagues in a global team environment.
  • Strong technical skills.
  • Strong communication and business writing skills.
  • Fluency in English.
Responsibilities
  • Compile, publish, and verify submission dossiers in accordance with international eCTD requirements.
  • Act as a team leader, providing direction, support, and mentorship to the publishing team.
  • Oversee the compilation, publishing, and verification of submission dossiers in accordance with international eCTD requirements and regulatory guidelines.
  • Lead and manage the submission of MAA, INDs, NDAs, BLAs, Master Files, and other regulatory documents.
  • Work closely with team members to compile documents, review hypertext links, ensure PDFs are submission ready, format tables and graphics, bookmark sections, and proof submissions according to internal standards.
  • Develop and implement new processes and procedures to enhance efficiency and accuracy during the submission process.
  • Collaborate with submissions management to build technically valid and high-quality dossiers.
  • Manage the submission of eCTD sequences through health authority gateways.
  • Perform quality control (QC) of documents published by team members to ensure compliance with applicable guidance documents.
  • Assist with the remediation of Word documents to ensure proper format and compliance.
  • Mentor and train team members to increase the quality across the team.
  • Participate in internal and external audits, maintaining compliance with department systems, e.g., project database, timesheets, training.
  • Contribute to the development of new publishing services and actively participate in department initiatives and process improvements.
  • Maintain a strong understanding of applicable regulatory guidelines and ensure the achievement of individual and team utilization targets.
  • Act as the primary point of contact for the team, providing regular updates to senior management on project status and any issues affecting quality, timelines, and adherence to contractual obligations.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to harness the body's own cellular machinery for healing. The company's goal is to improve patient outcomes by transforming the way medicines are discovered, developed, and manufactured, ultimately enhancing the lives of patients.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

0%

1 year growth

2%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna received $176 million to develop a bird flu vaccine in July 2024.
  • A new mRNA facility in Melbourne enhances response to Asia-Pacific virus outbreaks.
  • Moderna's collaboration with OpenAI could innovate AI-driven vaccine solutions.

What critics are saying

  • Declining COVID-19 vaccine demand impacts Moderna's stock and revenue forecast.
  • Bypassing safety steps in Australia may lead to regulatory scrutiny.
  • Geopolitical risks affect Moderna's investment in a new plant in China.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company focuses on mRNA to improve drug discovery and manufacturing.
  • Moderna's mRNA technology is considered the 'software of life' for cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend